<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Molecular Immunology and Genetics of Inflammatory Muscle Diseases</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Marinos</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Neuromuscular Diseases Section</orgName>
								<orgName type="department" key="dep2">National Institute of Neurological Disorders and Stroke</orgName>
								<orgName type="institution">National Institutes of Health</orgName>
								<address>
									<settlement>Bethesda</settlement>
									<region>Md</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Molecular Immunology and Genetics of Inflammatory Muscle Diseases</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">C02EFC29DA8F7B479C89315A0456870A</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>P</head><p>olymyositis, dermatomyositis, and inclusion body myositis, although immunopathologically distinct, share 3 dominant histological features: inflammation, fibrosis, and loss of muscle fibers. Progress in molecular immunology and immunogenetics has enhanced our understanding of these cellular processes. Based on the T-cell receptor gene rearrangement, the autoinvasive CD8 + T cells in polymyositis and inclusion body myositis, but not dermatomyositis, are specifically selected and clonally expanded in situ by heretofore unkown muscle-specific autoantigens. The messenger RNA of cytokines is variably expressed, except for a persistent up-regulation of interleukin 1␤ in inclusion body myositis and transforming growth factor ␤ in dermatomyositis. In inclusion body myositis, the interleukin 1, secreted by the chronically activated endomysial inflammatory cells, may participate in the formation of amyloid because it up-regulates ␤-amyloid precursor protein (␤-APP) gene expression and ␤-APP promoter and colocalizes with ␤-APP within the vacuolated muscle fibers. In dermatomyositis, transforming growth factor ␤ is overexpressed in the perimysial connective tissue but is down-regulated after successful immunotherapy and reduction of inflammation and fibrosis. The degenerating muscle fibers express several antiapoptotic molecules, such as Bcl-2, and resist apoptosis-mediated cell death. In myositis, several of the identified molecules and adhesion receptors play a role in the process of inflammation, fibrosis, and muscle fiber loss, and could be targets for the design of semispecific therapeutic interventions.</p><p>Arch Neurol. 1998;54:1509-1512   Distinct clinical, histological, and immunopathologic characteristics separate the acquired inflammatory myopathies into dermatomyositis (DM), polymyositis (PM), and sporadic inclusion body myositis (s-IBM). <ref type="bibr" target="#b0">1</ref> In DM, early activation of complement leads to the deposition of membranolytic attack complex on the endomysial capillaries, resulting in perivascular inflammation, capillary depletion, muscle ischemia, necrosis, and muscle fiber atrophy. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref> In PM and IBM, sensitized CD8 + cytotoxic T cells invade and destroy muscle fibers that aberrantly express class I major histocompatibility complex antigen. Abnormal mitochondria and vacuoles containing 15-to 18-nm tubulofilaments that immunoreact for ␤-amyloid and amyloid-related proteins are important factors in the pathogenesis of s-IBM. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref> Despite their clinicohistological and immunopathologic differences, the end result of the affected muscles in PM, DM, and s-IBM associated with clinical symptoms is the triad of chronic inflammation, fibrosis, and the loss of muscle fibers. This review focuses on the recent advances in molecular medicine that relate to the antigenic specificity of the infiltrating T cells and their T-cell receptors (TCRs) and the participating role of certain adhesion or regulatory molecules in fibrosis and the death of myofibers.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TCR GENE REARRANGEMENT OF ENDOMYSIAL INFLAMMATORY CELLS</head><p>The T cells recognize an antigen by the TCR, a heterodimer of 2 ␣ and ␤ chains, encoded by multiple gene families in the V (variable), D (diversity), J (joining), and C (constant) regions of the TCR. The part of the TCR that recognizes an antigen is the CD3 region, which is encoded by genes in the V-J and V-D-J segments of the TCR gene. If the endomysial T cells are selectively recruited by a musclespecific autoantigen, the use of the V and J genes of the TCR should be restricted, and the amino acid sequence in their CD3 region should be conserved. Three independent laboratories (Department of Neurology, Stanford University School of Medicine, Stanford, Calif, along with the Istituto Nazionale Neurologico "Carlo Besta," Milan, Italy; National Institutes of Health [NIH], Bethesda, Md; and Neuroimmunology Laboratory, Max Planck Institute, Martinsried, Munich, Germany) have examined the TCR gene families of the infiltrating or the autoinvasive CD8 + T cells with polymerase chain reaction and immunocytochemistry and showed that in patients with PM, but not in those with DM, only certain T cells of specific TCRα and TCRβ families are recruited to the muscle from the circulation. <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref> Cloning and sequencing of the amplified endomysial or autoinvasive TCR gene families demonstrated a restricted use of the Jβ gene with conserved amino acid sequence in the CD3 region. These findings indicate that in PM, the CD8 + cells are specifically selected and clonally expanded in situ by muscle-specific autoantigens, the nature of which remains unknown. Such antigens, presented to the autoinvasive CD8 + T cells by the class I major histocompatibility complex antigen on the sarcolemma, are expected to be either endogenous muscle peptides or viruses. The failure, however, by several laboratories to amplify known viral RNA from muscles affected by PM points to endogenous muscle proteins, rather than viruses, as the likely candidate autoantigens. <ref type="bibr" target="#b0">1</ref> In patients with s-IBM, similar studies have also shown an oligoclonal pattern of the TCRV gene expression. In contrast to the case in PM, however, in s-IBM the use of the Jβ genebytheendomysialTcellswasrandomandthesequences in the CD3 region inconsistent, suggesting a non-antigenspecific T-cell recruitment. <ref type="bibr" target="#b5">6</ref> New observations combining immunocytochemistry with polymerase chain reaction and sequencing of the most prominent TCR families have shown that the autoinvasive, but not the perivascular, CD8 + cells are also clonally expanded in patients with s-IBM. <ref type="bibr" target="#b6">7</ref> This finding is enhanced by our observations, based on sequential muscle biopsy specimens performed in a 2-year period in 3 patients with IBM that showed persisting clonal restric-tionofthesameV␤familiesamongautoinvasiveCD8 + Tcells. <ref type="bibr" target="#b7">8</ref> Despite the apparent resistance of s-IBM to immunotherapies, it appears that autoantigenic muscle peptides may also drive the T-cell activation in patients with s-IBM in a pattern similar to that in patients with PM. These observations complement the strong immunogenetic association of IBM with HLA-DR3 alleles, <ref type="bibr" target="#b8">9</ref> its frequent occurrence with other autoimmune diseases, <ref type="bibr" target="#b9">10</ref> and the immunopathologic features of T-cell-mediated and class I major histocompatibility complex-restricted cytotoxicity. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref> The nature of the muscle antigen and whether it is different or the same in PM and IBM remain to be determined.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ROLE OF CYTOKINES AND ADHESION RECEPTORS IN INFLAMMATION, FIBROSIS, AND AMYLOID</head><p>After binding to their receptors on the cell surface, cytokines induce dimerization and phosphorylation of the Janus Kinaje (JAK) family of kinases, followed by phosphorylation of the signal transduction and activation of transducers family of proteins that translocate to the nucleus for gene transcription and cell proliferation. In the muscle biopsy specimens of patients with PM, DM, and IBM, there is an overexpression of signal transduction and activation of transducers type I, indicative of cytokine up-regulation. This has been confirmed by polymerase chain reaction studies that have shown a varying degree of amplification of messenger RNA of interleukin (IL) 1, IL-2, tumor necrosis factor ␣, interferon gamma, transforming growth factor ␤ (TGF-␤), granulocyte-macrophage colony-stimulating factor, IL-6, and IL-10 (Figure <ref type="figure" target="#fig_0">1</ref>). The expression of each cytokine, however, has varied among the studied specimens of PM, DM, and IBM muscles and has not always related to the degree of endomysial inflammation. The exception has been for 2 pleiotropic cytokines that have been consistently up-regulated in the muscle tissues, IL-1␤ in IBM and TGF-␤ in DM (Figure <ref type="figure" target="#fig_0">1</ref>), prompting us to examine further their pathogenetic role for each disease.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TRANSFORMING GROWTH FACTOR ␤ AND DM</head><p>Transforming growth factor may be beneficial by suppressing the local inflammatory response or detrimental, when in excess, by stimulating the extracellular matrix proteins, resulting in fibrosis and chronic inflammation. <ref type="bibr" target="#b10">11</ref> Mice double knockout for the TGFb gene (Tgfb [−/−]) lack TGF-␤ and develop prominent endomysial inflammation similar to that seen in human PM (M.C.D., S. Wahl, PhD, unpublished observations, 1997). Because the adhesion of T cells is mediated by the upregulated integrins on their lymphocytic surface and cellular fibronectin is a ligand for ␤ 1 integrin, treatment of the Tgfb (−/−) mice with fibronectin peptides has suppressed the endomysial inflammation (M.C.D., S. Wahl, PhD, unpublished observations, 1997). These findings suggest that fibronectin or other small peptides that interfere with the binding of integrins to their respective ligands on the endothelial cell wall may provide new, promising therapeutic approaches for the treatment of patients with PM and DM.</p><formula xml:id="formula_0">M GAPDH IFN-γ TNF-α IL-1α IL-1β IL-2 IL-4 IL-6 TGF-β1 GM-CSF</formula><p>The deleterious effect of TGF-␤ in chronic inflammation and fibrosis is best evident in the muscles of patients with DM, where fibrosis is prominent and TGF-␤ and TGF-␤ messenger RNA are up-regulated. <ref type="bibr" target="#b11">12</ref> In the repeated muscle biopsy specimens of patients with DM who improved after successful immunotherapy, we have observed not only the suppression of class I major histocompatibility complex antigen, vascular cell adhesion molecule, intracellular adhesion molecule-I, endomysial inflammation, and fibrosis, <ref type="bibr" target="#b12">13</ref> but also substantial down-regulation of TGF-␤ and the TGF-␤ messenger RNA. More direct anti-TGF-␤ strategies, therefore, may be reasonable future therapeutic strategies in suppressing the deleterious inflammatory fibrosis in patients with DM.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IL-1␤ AND s-IBM</head><p>In s-IBM, the excess of IL-1␤ is derived by activated endomysial macrophages and T cells and probably by endomysial ␤-amyloid precursor protein (APP), which is a known enhancer of IL-1␤ production. <ref type="bibr" target="#b13">14</ref> There appears to be a closed loop between IL-1␤ and ␤-APP because IL-1␤ up-regulates the ␤-APP gene expression and ␤-APP promoter through protein kinase C. <ref type="bibr" target="#b13">14</ref> Consistent with these data is the observation that IL-1␤ co-localizes with ␤-APP not only in the amyloid plaques of patients with Alzheimer disease <ref type="bibr" target="#b14">15</ref> but also within the vacuolated muscle fibers of patients with s-IBM (Figure <ref type="figure">2</ref>). <ref type="bibr" target="#b15">16</ref> It can be proposed that the microglia in the brain and the macrophages in the muscle, both cells of the same lineage, promote through the production of IL-1 the evolution and continuous formation of amyloid in both the brain of patients with Alzheimer disease and muscle of patients with IBM, as depicted in Figure <ref type="figure" target="#fig_1">3</ref>.</p><p>The endomysial excess of IL-1␤ in patients with s-IBM may also be connected with the development of abnormal mitochondria and the ragged-red fibers that are commonly seen in this disease. In human myotubes, treatment with IL-1 causes cellular destruction and abnormal mitochondria that immunoreact with anti-IL-1 (C. Mora, MD, M.C.D., unpublished observations, 1996-1998). Furthermore, antiserum to IL-1 immunostains the subsarcolemmal mitochondrial accumulations of the ragged-red fibers in these patients' muscle biopsy specimens, as shown in Figure <ref type="figure">2</ref>. Because ragged-red fibers are seen only in s-IBM where inflammation is prominent, but not in the hereditary form of IBM where inflammation is absent, a connection of pathogenic significance may be proposed between chronic inflammation, IL-1␤ production, and mitochondrial toxicity.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>APOPTOTIC OR ANTIAPOPTOTIC MOLECULES IN PM AND IBM</head><p>Cytotoxic T cells induce cell death either through the perforin pathway or the Fas-Fas-L-dependent process. In PM and IBM, the autoinvasive activated T cells contain perforin granules that are reoriented toward the surface of the muscle fibers and, when released, induce pores on the plasma membrane, causing osmotic cell lysis. <ref type="bibr" target="#b17">18</ref> Whether the Fas-dependent pathway is also involved in myocytic cell death is unclear. Many of the regenerating and degenerating muscle fibers in patients with PM or IBM express the Fas antigen, <ref type="bibr" target="#b18">19</ref> and the autoinvasive CD8 +  cells express the Fas-L. Despite these Fas-Fas-L interactions, however, no signs of apoptosis have been detected in the muscle fibers of patients with inflammatory myopathies. This is the case even in the muscles of patients with myositis associated with human immunodeficiency virus infection where apoptosis of CD8 + cells takes place in the circulation. <ref type="bibr" target="#b19">20</ref> In the muscle, the expression of Fas does not seem to imply susceptibility to apoptosis, probably because the Fas-positive muscle fibers coexpress neural cell adhesion molecule or Bcl-2, a 26-kd antiapoptotic protooncogene protein, both molecules associated with regeneration or the prevention of apoptosis. <ref type="bibr" target="#b18">19</ref> Bcl-2 is also expressed on satellite cells, which renders the multinucleated muscle fibers even more resistant to apoptotic death. The balance of the interacting proapoptotic or antiapoptotic molecules and the signals responsible for the transduction of myocytic cell death in the inflammatory myopathies need further study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GENETICS IN HEREDITARY IBM</head><p>Among the autosomal recessive or dominantly inherited adult-onset, nondystrophic myopathies, there exists a heterogeneous group of vacuolar myopathies, collectively called hereditary IBM, owing to the presence of endomysial vacuoles and tubulofilamentous inclusions identical to those seen in s-IBM. <ref type="bibr" target="#b20">21</ref> Patients with hereditary IBM have various clinical phenotypes, some of which are prevalent in certain ethnic groups. <ref type="bibr" target="#b20">21</ref> One subset of hereditary IBM, initially described in Iranian Jews as a quadricepssparing, noninflammatory vacuolar myopathy, has now been seen in other ethnic groups in several countries-United States, Mexico, India, and Morocco-and has been linked to chromosome 9p. <ref type="bibr" target="#b21">22</ref> A clinicohistologically similar type of hereditary IBM described in Japan has also been linked to chromosome 9. When this area is narrowed down within a sequencing size, the gene responsible for hereditary vacuolar myopathies may be identified.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc>Figure 1. Cytokine messenger RNA expression in 3 patients with inflammatory myopathy shows a variable degree of cytokine amplification. Interleukin (IL) 1␤ and transforming growth factor ␤1 (TGF-␤1) are the strongest and most consistently amplified cytokines. M indicates molecular weight; GAPDH, glyceraldehyde-phosphate dehydrogenase; IFN-␥, interferon gamma; TNF-␣, tumor necrosis factor ␣; and GM-CSF, granulocyte-macrophage colony-stimulating factor.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Alzheimer and Down SyndromeFigure 3 .</head><label>3</label><figDesc>Figure 3.Proposed common pathways for the degeneration and aging brain (Alzheimer disease and Down syndrome) and inclusion body myositis (IBM) muscle demonstrating that interleukin 1 (IL-1) and ␤-amyloid precursor protein (␤-APP) co-up-regulate each other. In IBM, the ␤-APP is up-regulated by IL-1, which is secreted by the abundance of lymphocytes and macrophages that infiltrate the muscle prior to amyloid deposition. The up-regulated ␤-APP enhances the production of IL-1, which in turn stimulates ␤-APP and increases further the amyloid deposits. PNAS indicates Proc Natl Acad Sci U S A.</figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0">©1998 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ by a University of Illinois-Urbana Champaign User on 03/06/2023</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted for publication</head> March 2, 1998.   <p>I express my appreciation to K. Amemiya, PhD, and C. Semino-Mora, MD, PhD, for their contribution to the polymerase chain reaction and immunocytochemical studies.</p><p>Reprints: Marinos C. Dalakas, MD, Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Building 10, Room 4N248, 10 Center Dr, MSC 1382, Bethesda, MD 20892-1382.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Immunopathogenesis of inflammatory myopathies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S74" to="S86" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">The polymyositis and dermatomyositis syndromes</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Q</forename><surname>Banker</surname></persName>
		</author>
		<editor>Myology.</editor>
		<imprint>
			<date type="published" when="1994">1994</date>
			<publisher>McGraw-Hill Book Co</publisher>
			<biblScope unit="page" from="1335" to="1383" />
			<pubPlace>New York, NY</pubPlace>
		</imprint>
	</monogr>
	<note>2nd ed</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis: restricted V ␣/␤ rearrangements may indicate antigen-driven selection</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mantegazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Andreetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bernasconi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="2880" to="2886" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Predominant TCR-␣␤ variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>O'hanlon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="2569" to="2576" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8 + T cells</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ernst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Iglesias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dornmair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wekerle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">181</biblScope>
			<biblScope unit="page" from="1863" to="1868" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">The ␣␤ T-cell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscleinfiltrating lymphocytes</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>O'hanlon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Autoimmun</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="321" to="333" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">T-cell heterogeneity in muscle lesions of inclusion body myositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Behrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="86" to="91" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The T-cell receptor repertoire of endomysial lymphocytes in patients with inclusion body myositis (IBM) remains restricted over time: studies in repeated muscle biopsies</title>
		<author>
			<persName><forename type="first">K</forename><surname>Amemiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page">204</biblScope>
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Koffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sivakumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Simonis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Stronek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="139" to="142" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Autoimmune diseases and autoantibodies associated with sporadic inclusion body myositis</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Koffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rugiero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="115" to="117" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor ␤1 knockout mice</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Hines</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Kulkarni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Mccarthy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="5187" to="5191" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Transforming growth factor-␤1 in polymyositis and dermatomyositis correlates with fibrosis but not with mononuclear cell infiltrate</title>
		<author>
			<persName><forename type="first">P</forename><surname>Confalonieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bernasconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cornelio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mantegazza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="479" to="484" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Illa</forename><forename type="middle">I</forename><surname>Dambrosia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">329</biblScope>
			<biblScope unit="page" from="1993" to="2000" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Interleukin 1 regulates synthesis of amyloid ␤-protein precursor mRNA in human endothelial cells</title>
		<author>
			<persName><forename type="first">D</forename><surname>Goldgaber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="7606" to="7610" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Interleukin-1 expression in different plaque types in Alzheimer&apos;s disease: significance in plaque evolution</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Griffin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Sheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Mrak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="276" to="281" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Upregulation of IL-1␤ mRNA in inclusion body myositis (IBM) and co-expression with ␤-amyloid precursor protein: a mechanism for amyloid deposits</title>
		<author>
			<persName><forename type="first">C</forename><surname>Semino-Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page">204</biblScope>
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Buxbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Oishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">I</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="10075" to="10078" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">N</forename><surname>Goebels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Michaelis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Engelhardt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="2905" to="2910" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Cytotoxic mechanisms inflammatory myopathies: co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells</title>
		<author>
			<persName><forename type="first">L</forename><surname>Behrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="929" to="938" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1205" to="1209" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Inclusion body myositis and myopathies</title>
		<author>
			<persName><forename type="first">K</forename><surname>Sivakumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Neurol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="413" to="420" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Hereditary inclusion body myopathy maps to chromosome 9p1-q1</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mitrani-Rosenbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Argov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Blumenfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Seidman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Seidman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Mol Genet</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="159" to="163" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
